HALO logo

HALOZYME THERAPEUTICS INC

HALONASDAQ
🏆 #642 by market capEarnings Nov 2US Equity
$852.87▼ $52.28 (−6.13%)
Simulated price
1h—
24h▼ 6.1%
7d—
14d—
30d—
1y—
🏦Market Cap
$11.65B
Mid Cap
📈Revenue Growth (YoY)
+41.1%
High Growth
📊Gross Margin
82.4%
High
💵FCF Margin
35.4%
Strong
⚖️P/S Ratio
7.1x
Fair
Otter Score
44
Weak
📊

Analyst Ratings

Price
$852.87
Total
27
Raised
2
Lowered
2
Avg PT
$103.00
H / L
$115 / $90
InstitutionActionRatingDate
HC Wainwright & Co.
ReiteratedBuy2026-07-21
Morgan Stanley
ReiteratedOverweight2026-05-12
Benchmark
ReiteratedBuy2026-02-19
Wells Fargo
ReiteratedEqual Weight2026-02-19
TD Cowen
ReiteratedBuy2026-01-08
Goldman Sachs
ReiteratedNeutral2025-11-18
Citizens
ReiteratedMarket Outperform2025-11-04
JP Morgan
ReiteratedNeutral2025-10-27
Leerink Partners
UpgradedUnderperform → Market Perform2025-10-14
JMP Securities
ReiteratedMarket Outperform2025-08-06
Piper Sandler
ReiteratedNeutral2025-01-10
SVB Leerink
DowngradedOutperform → Market Perform2023-03-16
Evercore ISI Group
ReiteratedOutperform2021-06-14
Berenberg
ReiteratedBuy2020-12-17
Citigroup
ReiteratedNeutral2020-06-15
Canaccord Genuity
ReiteratedBuy2020-05-19
BMO Capital
ReiteratedOutperform2020-05-12
Cantor Fitzgerald
ReiteratedOverweight2020-05-04
Barclays
ReiteratedEqual Weight2020-02-25
Deutsche Bank
ReiteratedBuy2016-11-03
PiperJaffray
ReiteratedOverweight2016-09-16
MLV & Co.
ReiteratedBuy2014-12-24
Jefferies
ReiteratedUnderperform2014-09-15
UBS
UpgradedNeutral → Buy2014-06-11
Wedbush
DowngradedOutperform → Neutral2013-01-30
Brean Capital
ReiteratedBuy2012-04-16
Oppenheimer
ReiteratedOutperform2012-04-16
One row per institution, most recent rating